by Javid Syed On December 8, 2010 the World Health Organization (WHO) endorsed the use of the new Xpert® MTB/RIF test as the initial test offered to people suspected of having HIV-associated TB or multidrug-resistant (MDR) TB. The test, developed…
This is the 2nd Edition of the Treatment Action Group and Stop TB Partnership’s 2011 report on funding trends for tuberculosis (TB) research and development (R&D) from the baseline year 2005 through 2010, the last year for which full data is available.
Letter from TAG and other civil society organizations.
HIV, Hepatitis C Virus (HCV), and Tuberculosis Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development Second Edition September 2011 Written by Polly Clayden, Simon Collins, Mark Harrington, Richard Jefferys, Tracy Swan, Javid Syed, and Claire Wingfield with a a contribution…
July 2011 Globally in 2008 there were an estimated 440,00 cases of incident multidrug-resistant tuberculosis (MDR-TB). Despite international calls for action to reach universal access to TB treatment by 2015, governments and ministries of health in high-burden countries have not…
A strategic vision for R&D into point-of-care testing in resource-poor settings Tuberculosis (TB) remains a major challenge to public health globally, particularly in resource-poor settings. August 2011 – Although most cases of TB are curable, tuberculosis causes around 2 million…
On November 12, 2010, the Treatment Action Campaign (TAC) and partners jointly sent an open letter to Cepheid calling for affordable and expanded access to the GeneXpert® MTB/RIF TB diagnostic test. Following this correspondence, TAC and partners had a teleconference with FIND and Cepheid, during which Cepheid indicated that prices for the GeneXpert would be reduced. During December, FIND announced that it had negotiated a volume-based price reduction agreement with Cepheid, lowering the cost of the GeneXpert.
The new drug, diagnostic, and vaccine pipeline has never looked more promising for people with HIV, hepatitis C virus (HCV), and tuberculosis (TB), according to a report released today by Treatment Action Group (TAG) and HIV i-Base.
The global response to help countries scale up treatment of multidrug-resistant tuberculosis (MDR-TB) is underfunded and ineffective, according to a new report released today by three medical and medical advocacy organisations. A 20-month effort to reform the Green Light Committee Initiative, a World Health Organization (WHO)-hosted programme designed to help countries gain technical support for scale up of MDR-TB and access to quality-assured MDR-TB drugs, needs to be closely monitored to see if the reforms will address many key bottlenecks.
February 7, 2011 Dear Secretary Clinton, We write to ask for your leadership in ensuring The Global Fund to Fight AIDS, TB, and Malaria is “open for new business,” saving lives through expanding programming in 2012. We ask that you…